Last reviewed 2026-04-19 · How we verify

ALEGLITAZAR

Aleglitazar is being studied to see if it can lower cardiovascular risk and improve heart function in people with diabetes.

Aleglitazar is an approved drug studied for its potential to reduce cardiovascular risk. Clinical trials have evaluated its effects on cardiac energetics and function, as well as its use in treating type 2 diabetes. It has been investigated in various phases of clinical development, including Phase 3 trials.

At a glance

Mechanism of action

Aleglitazar's mechanism involves impacting cardiac energetics and function. Studies are exploring how it affects the heart's ability to produce and use energy. This research aims to understand if Aleglitazar can improve heart health in individuals with certain medical conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos in Patients With Type 2 Diabetes and NYHA Class II Heart Failure. (Phase 2)
• A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE THE RISK OF END STAGE RENAL DISEASE AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE (Phase 3)
• A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES (Phase 3)
• A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 (Phase 3)
• A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Aleglitazar 150 µg in Type 2 Diabetic Patients Treated With Lisinopril 20 mg on Renal Function, the R (Phase 1)
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Plus Metformin Combination Therapy Compared With Placebo Plu (Phase 3)
• A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes. (Phase 2)
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR PLUS METFORMIN COMBINATION THERAPY COMPARED WITH PLACEBO PLU (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.